We previously demonstrated that natural killer (NK) cells generated after haploidentical stem-cell transplantation (SCT) are blocked at an immature state characterized by phenotypic features and impaired functioning and that this may affect transplantation outcome. We hypothesize that the absence of mature donor T cells in the graft may affect NK cell differentiation. NK cells from 21 transplant recipients who underwent either partial (pTCD; n ¼ 11) or extensive (eTCD; n ¼ 10) T-cell depletion were compared with NK cells from their healthy donors. We report that despite the strong graft-versus-host disease (GvHD) reaction, pTCD patients, with T cells present during SCT, had a better clinical outcome than patients with eTCD transplants. In addition, the frequency of CD3 À CD56 bright and NKG2A
Introduction
Human natural killer (NK) cells, which are potent effector cells involved in clearance of virus-infected and tumor cells, recognize potential target cells without the need for immunization or preactivation by antigen-presenting cells. NK cell activity is mediated by the balance of activating and inhibitory signals sent by cell surface receptors. 1, 2 Under physiological conditions, target cells are protected from NK-mediated cytotoxicity because NK cells express inhibitory receptors that recognize epitopes shared by certain major histocompatibility complex class I allele groups. Some of these inhibitory receptors belong to the immunoglobulin superfamily, that is, they are killer cell Ig-like receptors (KIRs) that recognize classic class I human leukocyte antigen (HLA) alleles. Others belong to the lectin-like family, specifically, CD94/NKG2 receptors that recognize nonclassic class Ib HLA-E molecules. These inhibitory receptors are clonally distributed and constitute a repertoire that contains different allospecificities and prevents autologous lysis. 3 Natural killer cells can also recognize tumors that might evade T-cell killing by aberrant HLA expression or by expression of HLA molecules that are not recognized by any inhibitory NK receptors. Such situation exists in vivo in haploidentical T-celldepleted stem-cell transplantation (SCT), where NK cells play a remarkable role in patients with acute myeloid leukemia (AML) who receive haploidentical SCT with KIR ligand incompatibility in the graft-versus-host (GvH) direction. [4] [5] [6] Similar results are reported in unrelated SCT without any ex vivo T-cell depletion and with one or more HLA mismatches in the GvH direction. 7 Nonetheless, several studies also report that SCT with KIR ligand incompatibility either provides no survival advantage or results in a disadvantage. [8] [9] [10] Clues to understanding these discordant results may lie in the study of post-SCT NK reconstitution, where the role of NK cells in the graft-versus-leukemia effect can be examined in haploidentical SCT. The process of in vivo NK maturation from stem cells remains unclear, but in vitro the acquisition of activating and inhibitory receptors is sequential: CD94/NKG2A is first expressed on immature NK cells, and KIRs are expressed later on mature NK cells. 11 Recently, we observed the absence of a graft-versus-leukemia effect in 10 patients with AML who received haplo-mismatched SCT, despite the mismatched KIR ligand in the GvH direction for 8 of 10 patients. 12 This study showed that the NK cells generated after haploidentical SCT were characterized by specific phenotype features and impaired functioning. These findings suggested, according to in vitro models, that NK cells are immature after haploidentical SCT and that this may affect immune responsiveness and transplantation outcome. 12 Recent studies point out that adaptive immune cells, such as dendritic or T cells, play a role in NK cell differentiation and activation. [13] [14] [15] In HLA-mismatched haploidentical SCT, the substantial risk of severe graft-versus-host disease (GvHD) can be prevented by purified preparation of CD34 þ stem cells that have been depleted of CD3 þ T cells. 4 Recently, Cooley et al. 16 showed in unrelated bone marrow transplantation with either unmanipulated or T-cell-depleted transplants that T cells in the graft altered the clinical outcome: the presence of T cells was correlated with more GvHD and decreased KIR expression. Other findings, however, suggest that some degree of GvHD after SCT may be associated with successful outcome. 17 The aim of this study was to compare the reconstitution of the NK cell compartment during the first 5 months after haplomismatched SCT in two groups of patients, one undergoing partial (pTCD) and the other extensive T-cell depletion (eTCD). We analyzed the phenotypic expression of CD56, natural cytotoxicity receptors, major KIRs and CD94/NKG2A receptors on NK cells in both groups of transplant patients, as well as their cytolytic activity against K562 cells and AML blasts.
Materials and methods

Study patients and donors
Twenty-one adult patients received hematopoietic SCT from fully haplo-mismatched related donors at Mondor and Pitié-Salpêtrière Hospitals in France from 1995 through 2003. All patients had advanced malignant hematopoietic disease (refractory to chemotherapy or in a second or third remission). Table 1 summarizes the patient's characteristics. Patients received infusions of positively selected (by granulocyte colony-stimulating factor mobilization) peripheral blood CD34 þ stem cells characterized either by pTCD (ranging from 1.4 to 23 Â 10 5 kg À1 ) (pTCD group) or by eTCD (o1 Â 10 5 kg À1 ) (eTCD group) ( Table 1 ). The degree of T-cell depletion was associated with the separation technique used to purify the CD34 þ cells. In the pTCD group, 10 of 11 patients received CD34 þ cells selected by using an immunoadsorption biotinavidin column from CellPro (Bothell, WA, USA). By contrast, the MACS immunomagnetic beads technique (Miltenyi Biotec, Bergisch Gladbach, Germany) was used for the more recent CD34 þ cell purifications, for all patients of the eTCD group and one patient of the pTCD group. The latter procedure is known to induce more eTCD than the CellPro technique. 18 The groups were separated at a cutoff of 1 Â 10 5 T CD3 þ per kg, the generally accepted threshold for limiting GvHD risk in haploidentical settings. 19 Patients underwent the conditioning regimen previously described, 12 which combined total body irradiation with subsequent anti-T-cell globin, thiotepa and supportive care. 20 In addition, patients from the eTCD group received fludarabine, whereas the pTCD patients received cyclophosphamide (except for one patient who received fludarabine). No post-grafting immunosuppressive treatment, including cyclosporine, was given for GVHD prophylaxis. Patients and donors provided informed consent in compliance with the Ethics Committee guidelines before peripheral blood samples were collected for the study.
HLA typing
HLA-A and -B were serologically determined. The INNO-LiPa kit (Abbott Laboratories, Abbott Park, IL, USA) was used to type HLA-C with PCR sequence-specific oligonucleotides.
Cytofluorometric analysis
Four-color FACS analysis was performed on freshly harvested blood cells. Isotype-matched immunoglobulin served as the negative control. NK cells were analyzed after staining with an appropriate antibody cocktail: anti-CD45 (HI30) (BD Biosciences, Le Pont de Claix, France), anti-CD19 (HIB19) (BD Biosciences), anti-CD3 (UCHT1) (BD Biosciences), anti-CD56 NK cell preparation and cytolytic assays NK cells were purified and then cultured in the presence of 100 IU ml À1 interleukin (IL)-2 (Roche, Strasbourg, France) for 48 h, as previously described. 12 The cytolytic activity of NK cells was assayed in a standard 4-h 51 Cr-release assay, against either K562 cells or primary leukemic blasts from AML patients, as previously described. 12 The role of CD94/NKG2A was analyzed by adding an anti-NKG2A (Z199) mAb (Immunotech, Marseille, France) or its IgG2b isotypic control (BD Biosciences), at a final concentration of 20 mg ml À1 , and incubating them with the effector cells for 30 min at 37 1C.
12
NK IFN-g production and degranulation detected by flow cytometry Natural killer cells were incubated overnight with or without IL-12 (10 ng ml À1 ; R&D Systems, Lille, France) and IL-18 (100 ng ml
À1
; R&D Systems) to stimulate interferon (IFN)-g production, and for the last 5 h in the presence of Brefeldin A (0.4 ng ml À1 ), as previously described. 21 Cells were fixed and permeabilized with IntraPrep reagent (Beckman-Coulter) and then stained with APC anti-human IFN-g mAb (BD Biosciences).
The degranulation assay was performed by CD107a detection, according to methods previously described. 22 NK cells were incubated overnight with IL-2 and then resuspended at 10 6 cells ml À1 with target cells at a 1:1 ratio in the presence of anti-CD107a mAb (BD Biosciences). After 1 h of incubation, monensin was added at 6 mg ml À1 for an additional 5-h incubation. Number of male patients 6 4
Disease numbers Acute myelogenous leukemia 
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Statistical analysis
Statistical analyses used the Mann-Whitney U-test to compare the two groups. StatView 5.01 software was used, and P-values o0.05 were considered significant.
Results
Clinical outcome after haploidentical SCT
Survival, relapse and acute GvHD were different for the 11 patients in the pTCD group than for the 10 eTCD patients (Table 1 ). In the pTCD group, 3 of the 11 patients were in complete remission: one patient from chronic myeloid leukemia after 3 years and two patients from AML after more than 10 years. Outcome in the eTCD group, however, was poor, with no patients surviving for 12 months after SCT. The leading cause of death in this group was relapse (7/10), occurring in the early post-transplantation period. In the pTCD group, only one patient died of relapse. As expected, the presence of CD3 þ T cells in the pTCD CD34 þ transplants entailed a GvH reaction in all patients and caused five of the eight deaths. In contrast, the absence of GvH reaction in the eTCD group showed the very effective T-cell depletion in the CD34 þ transplant. Analysis of DNA polymorphisms in the peripheral blood of tested patients revealed full donor-type chimerism in all patients, 1 month after transplantation (data not shown).
Taken together, these clinical data show that pTCD patients, who had T cells present during the SCT, had a better clinical outcome, despite severe GvHD, than eTCD patients, who received highly purified CD34 þ transplants, regardless of any KIR mismatches in the GvH direction (Table 1 and data not shown).
Distribution of NK cell subsets after haploidentical SCT
Haploidentical SCT was used as a model to study in vivo the effect of T-cell depletion on NK cell reconstitution. Flow cytometry was used to measure CD3 þ , CD19 þ and CD3
À CD56 þ subsets in recipients throughout the follow-up and compare them to their healthy donors. There were no significant differences between the donors of both transplant types for any subsets. The presence of CD19 þ B cells was detected early in both groups, but earlier in the eTCD group (Figure 1a) . In eTCD patients, T cells, assessed by their frequency as well as their absolute number, were barely detectable after SCT and remained at low levels during the first 5 months after SCT (Figure 1b) . By contrast, the frequency of CD3 þ T cells in the pTCD group remained at a subnormal level after SCT, although the absolute numbers remained lower than in the healthy donors (Figure 1b) . In addition, CD3
À CD56 þ NK cells were detectable in all recipients soon after transplantation and remained at high levels throughout follow-up, with no significant differences between the two groups. The percentage of NK cells in recipients, compared with donors, was approximately 3.4 times higher (59.3 ± 18.5 versus 17.1±5.2%) (Figure 1c) . However, the absolute numbers of NK cells, in both patient groups, were similar in healthy donors and patients after haploidentical SCT, in agreement with previous observations. 16, 23 Natural killer cell populations were further subdivided into CD56 bright and CD56 dim populations. These phenotypes may reflect different stages in NK development or distinct regulatory and cytolytic NK sub-populations. 24 The CD56 bright NK subset was significantly higher in eTCD recipients than in donors during the 5 months after transplantation. The frequency of CD3 À CD56 bright NK cells in pTCD recipients, in contrast, was slightly higher than in donors but much lower than in eTCD recipients (25.0 ± 9.6 versus 53.3 ± 18.0%; Po0.001) at 3 months after transplantation (Figure 1d ). 25 As Figure 2a shows, NKp46 was expressed similarly by both groups of recipients throughout the first 5 months after transplantation. By contrast, however, NKp30 levels were significantly lower in eTCD than pTCD patients (58.0±6.5 versus 70.3±7.1%, P ¼ 0.013) at 3 months and remained so throughout follow-up (Figure 3a) . Interestingly, expression of NKp30 in pTCD patients after transplantation was similar to that in donors (70.3 ± 7.1 versus 76.9 ± 10.9%), thus suggesting that the cross-talk between NK and dendritic cells is more efficient in pTCD than in eTCD patients, as previously described. 26 NK cells from donors did not constitutively express NKp44, but a few NK cells did in recipients after transplantation: less than 10% in pTCD patients and 3-20% in eTCD patients. NKp44 was expressed mainly on CD3 À CD56 bright NK cells (data not shown).
NK receptor repertoire after haploidentical SCT
We further investigated the expression of the major inhibitory receptors and found that the frequency of CD94/NKG2A-positive NK cells was significantly higher in all recipients than in their donors after transplantation (93.4 ± 7.2 versus 49.6±10.9%; Po0.0001) (Figure 2b ). However, CD94/NKG2A expression was significantly lower in pTCD than in eTCD patients, from 3 months post-transplantation (P ¼ 0.034). In addition, CD3
À CD56 þ NK cells in recipients of both groups expressed sharply lower levels of KIR than in donors. Specifically, expression of KIR2DL1 (or KIR2DS1) and KIR2DL2/L3 (or KIR2DS2/DS3), which bind HLA-C ligands, was around 45 and 39%, respectively, lower than in donors, while the expression of KIR3DL1 (or KIR3DS1), which recognizes HLA-Bw4, was only 28% lower (Figure 2b ). Despite this generally lower KIR expression, its hierarchy within the KIRpositive population for each patient resembled that of the donor, thereby indicating that this expression was generally depressed in all recipients during the first 5 months, but not selectively disturbed for any particular KIR (data not shown). This reduced frequency of KIR expression in all recipients could not therefore be attributed to an alteration in the ratio of CD56 dim/bright cells, for this ratio differed significantly between the two groups (Po0.001; Figure 1d ).
Functional analysis of NK cells after haploidentical SCT
The results described above about the phenotypic abnormalities observed in patients may reflect an impairment of NK cell functional capacities in recipients during the 5 months after SCT. To verify this possibility, we assessed the spontaneous cytolytic activity of NK cells against K562 target cells. As shown in Figure 3a , NK cells from eTCD recipients displayed significantly worse cytolytic activity than those from donors, approximately 44% lower (P ¼ 0.035, Figures 3a and c, upper panel) . In contrast, NK cells from pTCD recipients had a cytolytic activity similar in magnitude to that of donor NK cells, around 69% for an effector/target ratio of 20:1 (Figures 3a and c, lower panel) .
Further studies used primary blasts derived from various HLAmismatched AML patients as target cells. These cells were first analyzed for susceptibility to killing by NK cells derived from healthy donors. As shown in Figure 3b , all AML blast cells were susceptible to killing by normal NK cells. Cytolytic activity nonetheless remained at much lower levels in eTCD recipients than in their donors (donor, 45.8 ± 19.1 versus recipient 6.7 ± 4.1%; P ¼ 0.001) (Figures 3b and c, upper panel) . For pTCD recipients, however, the level of cytolytic activity against AML blasts was approximately 4.3 times higher than in eTCD 
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patients (29.0 ± 3.6 versus 6.7 ± 1.7%; P ¼ 0.0002), although it remained lower than in donors (donor, 41.2±6.8 versus recipient 29.0 ± 8.9%; P ¼ 0.033) (Figures 3b and c, lower  panel) . Similar results were obtained with AML blasts provided from different patients.
Three months after SCT, we observed clearly different expression of CD94/NKG2A in the two patient groups (Figure 2b) . We have previously hypothesized that the inability to kill leukemic blasts may be due to overexpression of CD94/ NKG2A on NK cells following haploidentical SCT. 12 To verify this possibility, we assessed the cytolytic activity of NK cells in the presence of anti-NKG2A mAb against AML blasts with mismatched KIR ligands. AML blast expression of HLA-E, the ligand of CD94/NKG2A, was verified by western blot (data not shown). As Figures 4a and b show, cytotoxicity in eTCD patients was approximately twice as high in the presence of anti-NKG2A mAb than in controls, regardless of depletion type. In contrast, the anti-NKG2A mAb was ineffective in pTCD patients. Thus, despite the KIR ligand mismatch, lysis of AML blasts by NK cells following haploidentical SCT appears to depend on the differentiation state of NK cells in regard to the CD94/NKG2A expression.
To confirm the cytolytic activity of NK cells against AML blasts, we tested their degranulation capacities. The cell-surface mobilization of CD107a was more frequent in pTCD patients than in eTCD patients (P ¼ 0.001; Figure 4c ). However, consistently with the NK cytotoxicity data, the proportion of NKG2A þ NK cells expressing CD107a remained very low in both patient groups (Figure 4c ). 
Finally, we compared intracellular expression of IFN-g in NK cells from both patient groups and observed a higher fraction of IFN-g-producing NKG2A
þ NK cells in eTCD than pTCD patients (P ¼ 0.0003; Figure 4d ). This could suggest that NK cells from eTCD patients, a larger proportion of which are CD56 bright NKG2A þ IFN-g þ than in pTCD patients, remained blocked at an immature state.
Discussion
This study shows that the presence of T cells in the graft affects NK phenotypic and functional characteristics after haploidentical SCT. As previously shown, NK cells mature under the influence of the microenvironment and the host marrow stromal cells. 24, 27 Some forms of IL (such as IL-21), a cytokine produced by activated T cells, stimulate, in vitro and in concert with FLt3-L, stem cell factor and IL-15, maturation of NK cells and acquisition of KIRs. 28, 29 Several recent publications have focused on newly described interaction between NK cells and dendritic cells or T lymphocytes. 26, 30, 31 This cross-talk can first occur in secondary compartments, such as lymph nodes that are populated by NK cell subsets characterized by the CD56 bright CD94/NKG2A þ phenotype. 31 In Fehniger's study, 29 the residence of CD56 bright NK cells within a T-cell-rich region and their activation by T-cell-derived IL-2 suggests a link between adaptive and innate immunity. In addition, the noncytolytic CD56 bright lymph-node NK cells require IL-2 activation to express KIRs and CD56 dim and to be cytolytic. 32 Consistent with these data, a predominant cytotoxic CD56 dim subset of NK cells was observed in pTCD patients, close to the level in donors, associated with cytolytic activities against K562 cells and primary AML blasts. This level was higher than in eTCD patients, who expressed a large proportion of CD56 bright NK cells. In addition, after stimulation with cytokines, the overexpression of IFN-g production by NKG2A þ NK cells from eTCD patients confirmed that a higher proportion of these cells are blocked at an immature state than of NK cells from pTCD patients, as previously described. 33 The continuum along which stem cells differentiate into lineage-committed NK cells nonetheless remains unclear; CD56 bright cells are thought to be more primitive than CD56 dim cells. 24 In addition, we show that the processes of NK development might be modulated by the presence of mature donor T cells in the grafts; T cells may act directly by cytokine secretion or indirectly by their effect on the microenvironment, or both. 15 We observed low KIR expression in both groups, consistent with other studies: Shilling et al. 34 previously reported the persistence of low KIR expression during the first months after HLA-matched SCT and showed that it took 6 months to 3 years after SCT for the KIR repertoire to tend to recapitulate the donor repertoire. Similar results are also reported after unrelated bone marrow cell transplantation for chronic myeloid leukemia patients. 16 In addition, the evolution of CD94/NKG2A expression was significantly different in our patient groups and was strongly associated with a modulation of cytolytic activity. This 
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suggests that the presence of mature donor T cells in graft could induce differentiation of NK cells. This is consistent with the fact that a sharp CD94/NKG2A expression reflects a relative immaturity in NK cells. 11 Reduction of NKG2A is associated with reduced levels of CD56 and decreased IFN-g production and may be mediated by the transcription factor GATA-3, 35 also involved in IFN-g production. 36 We also investigated whether the infusion of a limited dose of donor leukocytes during transplantation might hasten immune recovery and prevent disease relapse. As previously suggested, 
we cannot rule out the possibility that mature donor NK cells in the graft exert an effect on immune recovery or graft-versusleukemia effect. 37 Zhang et al. 38 recently showed with deuterium-enriched glucose that the in vivo half-life of NK cells is less than 10 days, but Miller et al. 39 found an NK cell expansion lasting at least 138 days in leukemic patients infused with mature NK cells. Even though the three patients still alive in this study developed GvHD, possibly suggesting a T-cellmediated graft-versus-leukemia effect, we cannot determine whether this is relevant for long-term disease control, because two of these three donor-recipient pairs had a KIR ligand incompatibility in the graft-versus-host direction. After transplantation, all pTCD patients developed acute GvHD (grades II-IV), regardless of their NK cell incompatibility. The association of GvHD and NK cell alloreactivity in haploidentical transplantation contrasts with the study in mice by Ruggeri et al. 3 They observed that animals who underwent transplantation with haploidentical grafts that had NK cell alloreactivity against the host were protected against T-cell-mediated GvHD, apparently because of donor NK cell lysis of host antigen-presenting cells capable of initiating GvHD. As another difference with their findings, 4, 5 we observed leukemia relapse in 7-10 patients with KIR-ligand incompatibility in the direction of graft versus host, principally in the eTCD group. This suggests that, as previously described, 12 other factors including NK cell differentiation and disease status at transplantation also play a role in the ultimate attainment of long-term disease-free survival of patients with high-risk hemopathies.
In conclusion, persistence of mature donor T cells in the graft seems to enhance NK differentiation after haploidentical SCT and is, despite the strong GvHD reaction, associated with a better clinical outcome. Indeed, after pTCD transplant, the newly generated NK cells rapidly acquire phenotypes and functions close to those in donors as compared with the NK cells generated after eTCD transplant, which remain completely immature. The risk of severe GvHD remains high in partially T-cell-depleted haploidentical SCT, and it is unclear whether patients with such refractory diseases should be eligible for this type of transplantation. Hopefully, new protocols for NK cellmediated immunotherapies against human malignancies will soon be developed. Recently, a few pilot studies have tested the feasibility of mature NK cells infusion in leukemic patients and found that these adoptively transferred mature NK cells are well tolerated and can be expanded in vivo. 39, 40 The precise benefit of this strategy in leukemic patients cannot be definitively determined in these preliminary studies but should be assessed in subsequent larger clinical trials.
